Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in
approximately 30 patients with nail psoriasis for 16 weeks. Part 2 is an open-label extension
phase where all patients will receive active drug for an additional 16 weeks followed by a 2
week nontreatment period.